VWF Cleavage Fragment Detection for ADAMTS13 Activity Measurement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to measure the in vivo activity of ADAMTS13 and determine the efficacy of new recombinant VWF and ADAMTS13 products during preclinical and clinical studies, as well as test the effectiveness of therapies for ADAMTS13 deficiencies and von Willebrand disease, due to the inability to assess ADAMTS13 activity in the presence of endogenous VWF.
Innovation Solution
The development of methods using SDS-PAGE combined with immunoblotting and specific antibodies to detect and quantify VWF fragments, allowing for the measurement of ADAMTS13 activity by comparing VWF cleavage fragments in blood samples to reference curves, and assessing changes in VWF cleavage fragment levels before and after treatment to evaluate treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If in vitro methods are used to measure ADAMTS13 activity, then measurement can be performed under controlled conditions, but the ability to measure in vivo activity in the presence of endogenous VWF is lost
Solution Approach 1:
The patent uses a recombinant VWF substrate as an intermediary to measure ADAMTS13 activity. This substrate mimics endogenous VWF and can be used in both in vitro and in vivo settings, bridging the gap between controlled measurement conditions and physiological relevance. The recombinant VWF allows the assay to function as an intermediary that preserves measurement precision while enabling in vivo application.
Solution Approach 2:
The patent employs SDS-PAGE with varying molecular weight separation capabilities to detect different VWF cleavage fragments. By changing the separation parameters and using specific antibodies against different VWF regions, the method adapts to measure ADAMTS13 activity in complex biological matrices while maintaining measurement precision through controlled detection parameters.
2Measurement precision
If complex immunoblotting procedures are used to detect VWF fragments, then measurement specificity is improved, but assay complexity and time requirements increase
Solution Approach 1:
The patent segments the VWF detection process into distinct steps: SDS-PAGE separation of VWF fragments, transfer to membrane, and specific antibody detection. This segmentation allows each step to be optimized independently, maintaining high specificity while making the overall procedure more manageable and standardized.
Solution Approach 2:
The patent performs preliminary SDS-PAGE separation and membrane transfer before antibody incubation. This preliminary action pre-concentrates and pre-positionsthe VWF fragments, reducing the complexity of the subsequent detection step and improving specificity by ensuring that antibodies only bind to their target fragments in predetermined locations.
3Reliability
If high molecular weight VWF multimers are analyzed, then physiological relevance is improved, but detection and quantification difficulty increases
Solution Approach 1:
The patent replaces direct visualization methods with immunoblotting detection. Instead of attempting to directly observe and measure high molecular weight VWF multimers, the method uses antibody-antigen recognition and chemiluminescent or colorimetric detection, substituting mechanical/visual measurement with biochemical detection that is more sensitive and quantifiable.
Solution Approach 2:
The patent employs colorimetric or chemiluminescent detection systems where antibody binding to VWF fragments produces visible color changes or light emission. This allows high molecular weight VWF multimers to be detected and quantified through signal intensity rather than direct physical measurement, overcoming the difficulty of detecting large molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable the visualization and quantification of ADAMTS13 activity in vivo, allowing for the evaluation of new VWF and ADAMTS13 products and therapies, effectively measuring ADAMTS13 activity and treatment efficacy in conditions such as von Willebrand disease and thrombotic thrombocytopenic purpura.
Implementation Method 1
SDS-PAGE combined with immunoblotting
Implementation Method 2
immunoblotting using specific antibodies against VWF
Implementation Method 3
ADAMTS13 cleavage of the VWF monomers between Tyr1605 and Met1606
Data Source
AI summary
The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.